081 Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9, 000 patient-years of follow-up. (12th April 2019) - Fleischmann, Roy; Lin, Yong; John, Gregory St; van der Heijde, Désirée; Qiu, Chunfu; Gomez-Reino, Juan Carlos; Maldonado-Cocco, Jose Antonio; Stanislav, Marina; Seriolo, Bruno; Tranter, Lesley; Burmester, Gerd R